G lucocorticoidsarewidelyusedinseveralspecialties for their immunosuppressive and antiinflammatory properties. However, their use is limited by their well-recognized side-effect profile, includingthedevelopmentofhyperglycaemia.
Thevastmajorityofglucocorticoiduseisintheoutpatientpopulation.Epidemiologicaldatahaveshownthatin theUKapproximately0.75%ofthepopulationisonoral glucocorticoidtreatmentatanyonetime.Thisvariesfrom about 0.2% in under 30-year-olds to 2.5% in those between70and79yearsold (RoyalCollegeofPhysicians, 2002) .Ofthislong-termuse,40%isusedforrespiratory disease,withmostoftherestbeingusedforeithermusculoskeletalordermatologicalconditionsthatrequireimmunosuppression (RoyalCollegeofPhysicians,2002) .While the vast majority of glucocorticoid use is for less than 5days,overafifthisforover6monthswithabout4.3% beingreportedlyusedforover5years (Fardetetal,2011) .
Itiswellrecognizedthatlong-termglucocorticoiduse is associated with the development of hyperglycaemia, andobservationaldataformany-ifnotmost-medical andsurgicalconditionssuggestthattheadditionalpresence of hyperglycaemia or diabetes is associated with pooreroutcomes (Bakeretal,2006; Kwonetal,2013) . Thusthequestionarisesthatifsomanyspecialtiesprescribe these potentially harmful drugs, should the prescribers-astheyshouldwitheveryotherdrugtheyprescribe-takeresponsibilityforthepotentialconsequences ofthedrug.Shouldpatientsbecounselledonthepotentialharmsofthedrug?Beneficencevsnon-maleficence?
Differences between glucocorticoids
Different glucocorticoids have different potencies, as showninTable 1.Whilethemajorityofglucocorticoid useisinmedicalspecialities,thesesteroidsarealsocommonly used by anaesthetists as part of the enhanced recovery after surgery scheme to prevent postoperative nausea and vomiting. However, it is not known how manyindividualsundergoingsurgerywhoarenotpreviouslyknowntohavediabetesbutwhoweregivenreasonablyhighdosesofglucocorticoidhavetheirpre-orpostoperativebloodglucoselevelsmeasured,despiteevidence that postoperative hyperglycaemia is associated with harm (Frischetal,2010) .Recentlypublisheddatashow that the prevalence of inpatients on supraphysiological glucocorticoids was over 12%, yet only about 20% of thoseonglucocorticoidswerehavingtheirglucosemonitored (Swafeetal,2014) .
Pathophysiology of glucocorticoid-induced hyperglycaemia
High-dose glucocorticoids are used predominantly for theiranti-inflammatoryandimmunosuppressiveeffects. How they work is not completely understood, but it is thoughtthattheyactonglucocorticoidreceptorsinthe cytoplasmandnucleustosuppresstheexpressionofproinflammatorygenesandincreasetheexpressionofantiinflammatory genes, which in combination reduce the production of both arachidonic acid and prostaglandin pathway (FernandesandMcKay,2013) .
Glucocorticoids have several detrimental effects on carbohydratemetabolism.Theypromotevisceraladipose tissuedepositionandatthesametimeenhancelipolysis. They alter the levels of adipose tissue-derived cytokines and acutely increase hepatic glucose production. They also have very complex effects on beta cell function (SaltielandKahn,2001; Lambillotteetal,2008) . Inthelongertermtheydiminishtheabilityofinsulin toinitiateintracellularsignallingmechanismsintheliver, adipose tissue and muscle and thereby induce insulin resistance, which in turn inhibits glucose uptake into muscles and reduces oxidative phosphorylation (Hollingdaletal,2008; Petersonsetal,2013 
Lack of knowledge?
ThevastmajorityofinpatientcareintheUKisdelivered byjuniordoctors.Worklookingatlevelsofjuniordoctors'knowledgeaboutdiabetes,andassessingtheirlevels of confidence in managing the condition in this group, hasshownthatmostjuniormedicalstafflackevenabasic grasp of diabetes, and the majority have a poor understandingofitsmanagement(Georgeetal,2011).Inaddition,itispossiblethatseniormedicalstaffwhoroutinely prescribe high-dose glucocorticoids, e.g. those working inrheumatology,renalmedicine,oncology,haematology, gastroenterologyandrespiratorymedicine,maynotfocus ontheglycaemiceffectsofthisclassofdrug.Itmaywell be that this combination of junior doctors and senior doctorsbeingunawareofthispotentialeffectofglucocorticoidtherapymayleadtoglucosenotbeingmeasured.
Treatment options
Previousworkhasshownthathyperglycaemiainmedical patientsisassociatedwithincreasedriskofdeath (Baker etal,2006) .Therehavepreviouslybeenattemptstotry tofindtheoptimaltreatmentforsteroid-inducedhyperglycaemia.Theinitialmanagementwouldbeprevention -to try to educate the teams who routinely prescribe high-dose glucocorticoids in helping to detect steroidinduced hyperglycaemia early and to initiate treatment whenitisfirstfound.Inaddition,therehasbeensome worklookingatavarietyofdifferentdrugsusedtotreat thiscondition,butthereiscurrentlynoconsensus.
Thiazolidinediones work well in this condition and thereisacomplexinteractionbetweenglucocorticoidsin the PPAR (peroxisome proliferator-activated receptor) signallingpathwaythatareoftenthetherapeutictargets forthisclassofagents (Willietal,2002) .However,these drugsworkveryslowlyandsomaybeusefulintheoutpatient setting. Given the controversy surrounding this classofdrugsintermsoftheirside-effectprofiletheymay not be appropriate for many people.These side effects includeanincreaseincardiovasculardeathrates,increased distal forearm fracture rates, increased rates of macular oedemaandbladdercancer (Ryanetal,2006; Nissenand Wolski,2007; Lokeetal,2009; Ferwanaetal,2013) .
Sulphonylureasarewidelyused,butthereislittlepublished evidence for these. The Joint British Diabetes Societieshavewrittenaguidelineforthemanagementof inpatient steroid-induced hyperglycaemia which is due to be published shortly and will be freely accessible at www.diabetologists-abcd.org.uk/JBDS/JBDS.htm. Severalhospitalswereinvitedtosubmittheirguidelines for the management of this condition to the writing groupfortheseguidelinesandalmostallof them used sulphonylureasfirstorsecondline.However,veryfewof them gave any evidence for their use or references for this. Figures 1-3 show the pathways for people with 
No known diabetes
• Check random glucose before starting on steroids to identify patient with new onset hyperglycaemia
• If the capillary blood glucose is below 12 mmol/litre consider the patient to be at low risk and record the capillary blood glucose daily post breakfast or post lunch
• If the capillary blood glucose is found to be greater than 12 mmol/litre the frequency of testing should be increased to 4 times a day
• If the capillary blood glucose is found to be consistently greater than 12 mmol/litre (i.e. on two occasions during a 24-hour period), then the patient should enter the treatment algorithm below
If still no improvement on maximum dosage consider adding an evening dose of gliclazide or add morning human NPH insulin, e.g. Humulin I, Insulatard or Insuman Basal
Discharge: monitoring will need to be continued in patients remaining on glucocorticoids post discharge • If steroid treatment is ceased in hospital and hyperglycaemia has resolved capillary blood glucose can be discontinued post discharge • If steroids are discontinued before discharge and hyperglycaemia persists then continue with monitoring until normal glycaemia returns or until a definitive test for diabetes is undertaken (fasting blood glucose, oral glucose tolerance test or glycated haemoglobin)
Glycaemic targets:
• glucocorticoid-inducedhyperglycaemia,glucocorticoidinduceddiabetesandforthemanagementattheendof life.
Given their mode of action, incretin-based therapies would theoretically work very well in this situation because of their ability to prevent blood glucose rising, ratherthanloweringbloodglucose,butthereisverylittle experienceofuseofeitherglucagon-likepeptide-1ana-logues or dipeptidyl peptidase-4 (DPP-4) inhibitors in thiscircumstanceandthereremainsomesafetyconcerns abouttheirlong-termuse (Butleretal,2013) .Thereare somedatafortheuseofDPP-4antagonistsinhospital-ized patients, but very few of these individuals were reported as being on glucocorticoids (Umpierrez et al, 2013) .
Thebesttreatment,therefore,isprobablyinsulinand this has previously been recommended in the United States as the drug of choice for glucocorticoid-induced hyperglycaemia (HirschandPaauw,1997 
If steroids are reduced or discontinued:
• Blood glucose monitoring may need to be continued in inpatients and, in discharged patients assessed by their GP • Any changes made should be reviewed and consideration given to reverting to previous therapy or doses If unsure at any stage about next steps or want specific advice on how to meet the patient's needs or expectations please discuss with the team who usually looks after his/her diabetes (GP/specialist team).
• Reassess glucose control and current therapy
• Check capillary blood glucose four times a day and use this flowchart to adjust diabetes medication accordingly
• In type 1 diabetes also check daily for ketones if blood glucose >11 mmol/litre • In type 2 diabetes check for ketones if blood glucose levels still the same and the patient has osmotic symptoms Twice daily insulin:
• Morning dose will need to increase 10-20% daily according to pre-evening meal capillary blood glucose readings 
Glycaemic targets:
• Aim for 6-10 mmol/litre (acceptable range 4-12 mmol/litre)
• End of life care: Aim for 6-15 mmol/litre and symptom relief Insulin controlled (type 1 and type 2). In type 1 diabetes always test for ketones, If blood ketones more than 3 mmol/ litre or urinary ketones >++ assess for diabetic ketoacidosis In type 2 diabetes check for ketones if blood glucose levels still the same and the patient has osmotic symptoms If no 'hypo' symptoms and not on a sulfonylurea • Commence gliclazide 40 mg am, titrate until a maximum dose of 240 mg in the morning or glycaemic targets are reached • Seek specialist advice if you are concerned about dose titration in those taking 160 mg with no improvement in glycaemic control • If on twice-daily gliclazide and targets not reached consider referral to specialist care for titration to 240 mg morning dose plus 80 mg in the afternoon ©2014MAHealthcareLtd 6-10mmol/litre with a range of 4-12mmol/litre being acceptable.Onceagain,thesemaybedifficulttoachieve because of the added metabolic complexity of stress hyperglycaemia, altered nutritional intake and multiple interruptionstomedicalcarewhileinhospital.Thetargetsforend-of-lifecarearedifferent (Figure 3) . Foroutpatientusethereistheadvantageofgivingsubcutaneousinsulin,butthedifferenceswiththisregimen are that higher prandial doses are required than basal insulindoseswhencomparedwiththeuseofavariable rate intravenous insulin infusion. However, a potential limitationforfurtherrecommendationastowhichinsulintouseisthatnoworkhasbeendoneinthissituation tocomparehumaninsulintoanalogueinsulin.Thereare alsotheoreticalrisks,becausebasalinsulinwillneedtobe giventopreventhyperglycaemiaandtopreventhypoglycaemiabymismatchingprandialinsulindoseswithcarbohydrateintake.Closeliaisonwiththespecialistdiabetesteamwouldberequiredtoensurethatthetreatment isappropriate.
TheAmericanDiabetesAssociationhasformanyyears suggestedthatpeoplewhoarenotknowntohavediabetesandwhoreceiveglucocorticoidtherapyshouldmonitortheirbloodglucoselevelsregularly(AmericanDiabetes Association, 2014). They went on to suggest that if hyperglycaemiaispersistentthenbasalbolusinsulinmay benecessaryandtheglycaemicgoalsforsomebodywho wasnotpreviouslyknowntohavediabetesshouldbethe sameassomebodywhodoeshavediabetes.
Ofcoursethereisalmostnoevidencefortheserecommendations, with the American Diabetes Association acknowledgingthattheyareexpertopiniononly.Inadditionwhilethereremainsawealthofevidencesuggesting thathyperglycaemiaisassociatedwithharm,thereisvery littleevidencetoshowthatnormalizinghyperglycaemia isassociatedwithbenefit (Umpierrezetal,2002; Bruno etal,2008; Dhatariya,2013) .
Conclusions
Glucocorticoid-induced hyperglycaemia and glucocorticoid-induced diabetes remain conditions which are associated with harm and can worsen the underlying conditionforwhichtheglucocorticoidsarebeinggiven. The Joint British Diabetes Societies guidelines for the management of this condition in both outpatients and inpatientsshouldhelpaddresstheseissues.
The Joint British Diabetes Societies guideline recommendsthatregularbloodglucosetestingbeundertakenin all individuals without a previous diagnosis of diabetes who are given doses of glucocorticoids equivalent to a doseof≥7.5mgofprednisolonegivendailyeitherasan inpatient or as an outpatient, and that appropriate glucose-loweringmedicationsbeinitiatedifhyperglycaemia occurs.Inaddition,extramonitoringneedstotakeplace inpeoplewithanexistingdiagnosisofdiabetesandthat appropriateadjustmentsmadeintheirmedicationtokeep themwithintheirindividualizedglycaemictarget.BJHM Discuss changing the approach to diabetes management with patient and/or family if not already explored. If the patient remains on insulin ensure the diabetes specialist nurses are involved and agree monitoring strategy
• Keep tests to a minimum. It may be necessary to perform some tests to ensure unpleasant symptoms do not occur as a result of low or high blood glucose levels • It is difficult to identify symptoms caused by hypo-or hyperglycaemia in a dying patient • If symptoms are observed they could be the result of abnormal blood glucose levels • Test urine or blood for glucose if the patient is symptomatic • Observe for symptoms in previously insulin treated patient where insulin has been discontinued If patient requires rapid acting insulin † more than twice consider daily isophane insulin ‡ or Glargine (Lantus) 
